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a  b  s  t  r  a  c  t
A  strategy  adopted  by different  countries  to reduce  the  number  of  new  cases  of  hepatitis  A is  the  vac-
cination.  However,  the  mosaic  of  the  epidemiological  proﬁle  in  developing  countries  has hampered  the
establishment  of a uniﬁed  nationwide  vaccination  program.  To determinate  national  vaccination  poli-
cies,  the  results  of  epidemiological  studies  need  to  be carefully  considered.  For  this  monitoring,  the  use
of  oral  ﬂuid  is very  important  due  to the  painless  and  non  invasive  collection  characteristics.  There  are
few  studies  investigating  which  oral  ﬂuid  collection  device  is optimal  to detect  low  antibody  levels  and
its  use  in  selecting  individuals  for  vaccination.  So,  the  present  study  aimed  to evaluate  different  oral  ﬂuid
collection  devices  to detect  humoral  immune  response  against  hepatitis  A virus  and  its application  in
epidemiological  studies.  Therefore,  90  matched  serum  and  oral  ﬂuid  samples  were  collected  from  vol-
unteers  with  different  immune  status,  under  ideal  conditions  of  collection  (optimization  panel);  and  224
matched  samples  in  difﬁcult-to-access  areas  (epidemiological  study).  Serum  was  collected  by  venipunc-
ture  and the  oral  ﬂuid  was  obtained  using  three  commercial  devices:  Salivette®, OraSure® and  ChemBio®.
Serum  and  oral  ﬂuid  were  submitted  to  a commercial  immunoblot  to  detect  total  anti-HAV  antibodies.
The  optimization  panel  demonstrated  that  ChemBio® device  had the  best  performance  (100%  agreement),
followed  by  OraSure® (95.4%)  and  Salivette® (90.8%).  The  optimal  collection  device  (ChemBio®),  tested
in  a difﬁcult-to-access  area  and  evaluated  under  precarious  conditions  of  collection,  showed  similar
prevalence  of  total  anti-HAV  between  serum  and  oral  ﬂuid,  80.8%  and  79%,  respectively.  A follow-up  was
performed  to evaluate  the stability  of  oral  ﬂuid  and  it was  observed  that  210  days  after  the  collection  it
was  possible  to detect  anti-HAV  antibodies.  Oral  ﬂuid  can  be used  to detect  low  levels  of speciﬁc-antibody,
being  important  to select  age  groups  to be vaccinated.  Therewith,  the  choice  of proper  collection  device
is  essential  to evaluate  HAV  antibodies  in  the  epidemiological  scenario.. Introduction
Hepatitis A is an endemic illness in Brazil and mainly affects indi-
iduals during early childhood. However, because of improvements
n sanitary conditions, the epidemiologic pattern of the disease has
hanged, and there has been an increase in the number of clinically
vident cases in adolescents and adults [1].In countries with low or intermediate rates of the disease (USA
nd Argentina), a routine pediatric vaccination program is thought
o be the best strategy to control hepatitis A virus (HAV) infection
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swaldo  Cruz – FIOCRUZ, Cx Postal 926, Av. Brasil 4365, CEP: 21045-900, Rio de
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because children play a critical role in disease transmission [2,3].
The epidemiological pattern and economic factors of HAV should
be considered when selecting individuals and/or age groups for
vaccination to prevent hepatitis A outbreaks.
One strategy for understanding the epidemiology of hepatitis
A is investigating immunity status by detecting anti-HAV antibod-
ies in age-speciﬁc groups [4]. Although these studies, which are
based on anti-HAV prevalence, are conventionally performed using
serum samples, blood collection by venipuncture is invasive and
potentially painful [5]. Furthermore, the subsequent transport (to
avoid hemolysis), storage (temperature control), and processing
(centrifugation) of serum samples require speciﬁc conditions that
Open access under the Elsevier OA license.are mostly unavailable in surveillance settings. Thus, alternatives
to blood analysis are needed that are non-invasive and easy to col-
lect. Oral ﬂuid could be a satisfactory and convenient alternative to
blood analysis [6], particularly when considering children or other
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ndividuals from whom it is difﬁcult to collect blood specimens as
ell as communities in difﬁcult-to-access areas [7].
Although several studies have demonstrated the suitability of
ral ﬂuid as an alternative to serum for detecting HAV-speciﬁc
ntibodies [7–10], inadequate sensitivity and/or speciﬁcity of the
vailable tests makes these assays inappropriate for clinical use.
hese features are intrinsically related to the pathogenesis of HAV
nfection and are critical for evaluating the antibody response that
s induced by vaccination. The immune protection induced by the
AV vaccine is at least 10 times lower than that resulting from
atural infection [11], and it is more pronounced when using oral
uids, in which HAV-speciﬁc antibody concentrations are approxi-
ately 800–1000 fold lower than those observed in serum samples
12–14].
Currently, there are several available methods for collecting oral
uid. However, few community-based studies have investigated
hich method is optimal for anti-HAV detection; important factors
uch as low cost, ease of collection, the validity of the results when
he samples are stored under sub-optimal storage conditions, and
se in a low-tech setting should be considered [15]. The aim of
his study was to evaluate different oral ﬂuid collection devices
o determine which is more suitable for distinguishing between
AV-susceptible and -protected individuals in community survey
tudies.
. Materials and methods
.1.  Optimization panel of oral ﬂuid samples
The optimization panel was composed of matched serum and
ral ﬂuid samples collected from 90 health care workers without
pidemiological or clinical factors associated with acute or chronic
epatitis. The health care workers were from the Oswaldo Cruz
nstitute and were stratiﬁed according to the total anti-HAV status
f their serum. A total of 55 individuals had documented immunity
o HAV (post vaccination, n = 25; previous infection, n = 30), and 35
ndividuals were non-reactive for anti-HAV antibodies.
The optimization panel was designed to determine the opti-
al salivary collection device and the most favorable parameters
dilution, incubation time and temperature) for the detection of
ow titers of anti-HAV antibodies in a commercial immunoassay
ImmunoComb® II HAV Ab, Orgenics, Israel) using serum samples
s a reference (referred to as the “gold standard”).
.2. Sample collection and processing
Matched serum and oral ﬂuid samples were collected from each
articipant. Five milliliters (mL) of peripheral blood was  drawn
y venipuncture using hypodermic needles and multiple sterile
acuum blood collection tubes (Vacutainer system, Franklin Lakes,
J, USA). Subsequently, the samples were centrifuged at 1800 × g
t 25 ◦C for 5 min, and the sera were stored at −20 ◦C. Oral ﬂuid
amples were obtained with three different commercial devices:
hemBio® (ChemBio Diagnostic Systems Inc., NY, USA), OraSure®
originally provided as an HIV-1 Oral Specimen Collection Device)
Epitope Inc., Beaverton, USA), and Salivette® (Sarstedt, Germany).
ral ﬂuid sample collection and processing procedures are shown
n detail in Table 1.
.3.  Sample screeningTotal  anti-HAV antibodies were detected with a commercially
vailable, solid-phase enzyme immunoassay (EIA) based on the
rinciple of immunocapture (ImmunoComb® II HAV Ab, Orgenics,
srael). The solid phase is a comb composed of 12 projections. Each 30 (2012) 6421– 6426
projection  is sensitized at two  positions: an upper spot with a mon-
oclonal anti-HAV antibody (internal control) and a lower spot with
rabbit anti-human IgG and IgM antibodies.
The test was  performed according to the manufacturer’s instruc-
tions and adapted for oral ﬂuid samples; 25 L of oral ﬂuid was
added without sample diluents. The results of the test are visi-
ble as gray-blue spots on the surface of the projections, and the
visual results are determined semi-quantitatively by comparing the
intensity of the color of the lower spot on each projection with the
color scale provided by the manufacturer. The results of the sam-
ples were classiﬁed according to the cut-off point (10 IU/L) of the
test. A spot with an intensity greater to or equal than the cut-off
point indicated the presence of protecting anti-HAV levels. A spot
with an intensity slightly less than that of the cut-off was  consid-
ered an equivocal result, and the sample was  retested. A spot with
a lower intensity than that of the cut-off was  considered negative.
The ImmunoComb® II HAV Ab assay has a limit of detection of 10 IU
anti-HAV antibodies/L, which is regarded as the minimum con-
centration of anti-HAV antibodies that indicates immunization has
occurred. All of the samples were assayed three times, and identi-
cal visual readings for HAV were consistently observed by multiple
investigators (three) for all samples.
2.4. Applicability of the optimal salivary collection device in
surveillance settings
After  determining the optimal salivary collection device, its
applicability in a surveillance setting was determined. This study
was performed in four isolated communities in South Pantanal,
Brazil, in difﬁcult-to-access areas that are 661 km from the city of
Campo Grande. This region is sparsely populated and is character-
ized by wetlands that hinder access to the coastal communities;
access is only available by boat. For these reasons, ﬁshing is the
primary source of income and livelihood for the majority of the pop-
ulation. The survey was conducted between April and June 2010,
and the ChemBio® device was  used to collect 224 matched serum
and oral ﬂuid samples using a non-probability sampling method
from all consenting occupants of households. The entire population
consisted of 691 individuals. The samples were placed in a cool box
and returned to the laboratory after 15 days of collection for a total
anti-HAV screening test. The sociodemographic characteristics of
each member of the study were obtained with questionnaires.
2.5.  Effects of time exposure and temperature on the detection of
anti-HAV  antibodies in oral ﬂuids
The inﬂuence of temperature and time exposure on the detec-
tion of anti-HAV antibodies in oral ﬂuid samples was investigated.
The parameters were based on the manufacturer’s storage instruc-
tions. Five concordant, matched samples (3 anti-HAV positive and
2 negative) that were collected in difﬁcult-to-access areas of South
Pantanal were selected for follow-up to evaluate anti-HAV antibody
stability. Due to the unavailability of cooling in the surveillance
setting, the oral ﬂuid samples remained at unstable temperature
conditions for 15 days. At the end of this exposure, the samples
were sent to a laboratory in Rio de Janeiro and were centrifuged
and refrigerated at 2–8 ◦C until the ﬁrst analysis (15 days after col-
lection). The samples were stored for 210 days after collection and
were retested every 30 days.
2.6. Ethical aspectsEthical  permission for collecting and testing samples was  pro-
vided by the FIOCRUZ Ethical Committee (536/09), and written
informed consent was  obtained from each participant before
entering into the study. The specimens and questionnaires were
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Table  1
Description, collection, and extraction characteristics of the three commercially available oral ﬂuid devices used in the present study.
ChemBio®
Description A sponge swab attached to a handle with a plastic tube containing 500 L of preservative solution.
Collection  The swab is rubbed along the teeth/gum line for approximately 1 min, after which it is returned to the plastic tube.
Extraction Oral ﬂuid is concentrated at the bottom of the plastic tube by centrifugation at 1300 × g at 25 ◦C for 10 min  and stored at 2–8 ◦C.
OraSure®
Description A ﬂat absorbent cotton pad pretreated with 800 L of preservatives and stabilizing reagents supported by a plastic stem.
Collection The pad is placed against lower gum on one side and keeps stationary for 2 min.
Extraction As previously described and stored at −20 ◦C.
Salivette®
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Collection As previously described for OraSure® . The
Extraction As previously described and stored at −20
nonymous, and feedback was given to all participants of the study,
ncluding their results. All unprotected participants were advised
o be vaccinated against hepatitis A.
.7. Statistical analysis
Data  are presented as medians and frequencies. The perfor-
ance of the laboratory tests with the collected oral ﬂuid samples
as determined by comparing the sensitivity, speciﬁcity, and
ositive and negative predictive values and their respective 95%
onﬁdence intervals (95% CI) with the serum results, which were
sed as a gold standard control. The linear and weighted kappa
k) statistic was used to evaluate the rate of agreement between
he oral ﬂuid and serum anti-HAV antibody status for each device
sed. According to the strength of the agreement, the k value was
nterpreted as follows [16]: <20%: poor; 21–40%: fair; 41–60%:
oderate; 61–80%: good; and 81–100%: very good. To compare
roportions, the Chi-square (2) test for independence with Yate’s
ontinuity correction, 2 for trend, and Fisher’s exact test (when
ppropriate) were used. The Spearman’s coefﬁcient of rank cor-
elation (rs) was used to evaluate the degree of the relationship
etween the values of color intensity on the colorimetric scale
btained after using the oral ﬂuid collection devices. A two-tailed
 < 0.05 was considered statistically signiﬁcant. All analyses were
erformed with MedCalc for Windows, version 8.1.0.0 (MedCalc
oftware, Mariakerke, Belgium), and GraphPad InStat version 3.05
GraphPad Software, CA, USA) software.
. Results
.1. Determination of the optimal oral ﬂuid dilution for detecting
nti-HAV  antibodies
The  optimal oral ﬂuid dilution for detecting anti-HAV antibod-
es in the ImmunoComb® II HAVAb was determined using matched
amples from the optimization panel. Among the 30 individuals
ith natural immunity to HAV, oral ﬂuid samples collected by
raSure® and Salivette® devices presented concordant results with
hose from serum samples until a 1:25 dilution. However, false-
egative results were observed after the 1:5 dilution when the
hemBio® device was used. For the 25 HAV-vaccinated individ-
als, all of the diluted samples presented false-negative results,
rrespective of the oral ﬂuid collection device used. False-positive
esults were not observed in the group of 35 individuals who were
on-reactive for anti-HAV antibodies. Based on these ﬁndings, the
etection of anti-HAV antibodies by all of the devices was  opti-
al when undiluted oral ﬂuids were used; the evaluation of other
arameters (temperature, incubation time, etc.) was not required
o optimize these samples.ntaining an absorbent cotton wad.
 applied to the wad  1 mL  of phosphate-buffered saline (PBS).
3.2. Performance of oral ﬂuid collection devices for detecting
anti-HAV antibodies
The  rate of agreement between the oral ﬂuid and serum anti-
HAV antibody status for each device was  evaluated for each group
of individuals. Oral ﬂuid samples collected by OraSure®, Salivette®,
and ChemBio® yielded concordant results (k = 100%) with the cor-
responding serum samples in individuals with a natural immunity
to HAV and in individuals that were orally non-reactive for anti-
HAV antibodies. For the 25 HAV-vaccinated individuals, all of the
samples that were collected with ChemBio® device were reagent.
Two and four samples yielded false-negative results after collection
by OraSure® and Salivette®, respectively. However, half of these
false-negative results (1/2 – OraSure®) were observed in individu-
als that were not fully vaccinated (1 dose administered of a 2-dose
schedule) against HAV, while the other half (2/4 – Salivette®) were
observed in individuals that were fully HAV-vaccinated (2-dose
schedule completed).
When  analyzing the results from individuals with natural
immunity to HAV and those from HAV-vaccinated individuals, a
variation in the color scale values was observed in the oral ﬂuid
and serum samples. HAV-vaccinated individuals presented median
color scale values that were signiﬁcantly lower than those for indi-
viduals with natural immunity to HAV (p < 0.05). Moreover, there
was a signiﬁcant trend of values with a more intense color in the
samples from individuals with natural immunity to HAV relative to
those from HAV-vaccinated individuals (p < 0.05) (Table 2). Among
the oral ﬂuid devices used, ChemBio® yielded median values of
color intensity that were more similar to those of serum from
the group of HAV-vaccinated individuals (n = 25; p = 0.1250) than
from the total group of individuals with immunity to HAV (n = 55;
p = 0.0020).
ChemBio® was the most sensitive and speciﬁc of the tested oral
devices, with positive and negative predictive values equal to 100%.
A correlation analysis was used to evaluate how the values of the
visual readings of the color scale for the serum and oral ﬂuid corre-
spondingly changed for each oral ﬂuid device; a signiﬁcant positive
correlation existed between these two  variables (p < 0.0001).
The weighted kappa value revealed a perfect rate of agreement
(k = 100%) between the serum and oral ﬂuid samples collected with
the ChemBio® device. Moreover, the highest positive correlation
was found with the ChemBio® device. The parameters evaluating
the performance of the EIA used in the experiments are presented
in Table 3.
3.3.  Applicability of oral ﬂuid specimens for epidemiological studyAfter determining that the ChemBio® oral ﬂuid collection device
yielded the best results for the anti-HAV antibody detection test, an
epidemiological study was  conducted to assess the applicability of
this device in surveillance settings.
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Table  2
Level  of anti-HAV antibodies in individuals with immunity to HAV and evaluated by
visual reading of the color scalea (CombScaleTM) according to oral ﬂuid collection
devices.
Group Sample
Serum Oral ﬂuid collection device
ChemBio® OraSure® Salivette®
Vaccinateda (n = 25)
Median 2.0 2.0 1.0 1.0
Range 1.0–5.0 1.0–5.0 0.0–5.0 0.0–4.0
Color  scale (n/%) (n/%) (n/%) (n/%)
0  0 (0.0) 0 (0.0) 2 (8.0) 4 (16.0)
1  4 (16.0) 6 (24.0) 12 (48.0) 12 (48.0)
2  12 (48.0) 11 (44.0) 6 (24.0) 6 (24.0)
3 4  (16.0) 4 (16.0) 2 (8.0) 0 (0.0)
4 4  (16.0) 3 (12.0) 2 (8.0) 3 (12.0)
5 1  (4.0) 1 (4.0) 1 (4.0) 0 (0.0)
Natural  immunity (n = 30)
Median 4.0 3.0 3.0 3.0
Range  1.0–5.0 1.0–5.0 1.0–5.0 1.0–5.0
Color  scale (n/%) (n/%) (n/%) (n/%)
0  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1  1 (3.3) 3 (10.0) 4 (13.4) 5 (16.7)
2 5  (16.7) 4 (13.4) 7 (23.3) 7 (23.3)
3  8 (26.7) 10 (33.3) 8 (26.7) 6 (20.0)
4 15  (50.0) 12 (40.0) 10 (33.3) 11 (36.7)
5  1 (3.3) 1 (3.3) 1 (3.3) 1 (3.3)
p-Value† 0.0022 0.0054 0.0008 0.0003
a Presence of protecting anti-HAV antibodies levels is indicated by a spot with an
intensity greater than or equal to that of the cut-off point (10 IU/L).
† p < 0.05 (in bold) are statistically signiﬁcant. Vaccinated versus natural immunity
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Table 4
Total  anti-HAV results of serum and oral ﬂuid matched samples from a population-
based  prevalence study conducted in difﬁcult-to-access areas of South Pantanal
(n  = 224).
Serum+ Serum− Total
Oral ﬂuid+ 176 (78.6%) 1 (0.4%) 177 (79.0%)
Oral ﬂuid− 5 (2.2%) 42 (18.8%) 47 (21%)
Total 181 (80.8%) 43 (19.2%) 224 (100%)
Table 5
Effect  of time exposure and temperature for detecting anti-HAV antibodies in oral
ﬂuid.
Collection device Storage temperature Stability
ChemBio® Room temperature 2 yearsa
2–8 ◦C Up to 210 daysd
20 ◦C Not recommendeda
OraSure® Room temperature 21 daysb
2–8 ◦C 21 daysa
−20 ◦C 45 daysa
Salivette® Room temperature 5 daysb
2–8 ◦C 20  daysc
−20 ◦C 1 yeara
a According to manufacturer’s instruction for HIV test.
b According to Ref. [14].
c
best performance at both room temperature and 2–8 C relative to
T
P
a
†roups  (Chi-square for trend).
In a population-based prevalence study conducted in difﬁcult-
o-access areas of South Pantanal, 224 matched serum and oral ﬂuid
ChemBio®) samples were obtained from volunteers; 100 (43.9%)
f the volunteers were female, and 124 (56.1%) were male. The age
f the study population ranged from 3 to 86 years with a mean age
f 26.91 ± 17.35 years.
Total anti-HAV antibodies were detected in 181 sera sam-
les using the commercial immunoassay ImmunoComb® II HAVAb
Orgenics, Israel); the HAV seroprevalence was 80.80%. The preva-
ence of total anti-HAV yielded by the oral ﬂuid samples collected
ith the ChemBio® device was 79.01%, corresponding to 177 reac-
ive samples. Table 4 shows the concordant and discordant results
f the serum and oral ﬂuid matched samples. These data showed
hat the ChemBio® device had a sensitivity of 97.24% (95% CI:
.936–0.991), a speciﬁcity of 97.67% (95% CI: 0.877–0.999), a pos-
tive predictive value of 99.44% (95% CI: 0.968–0.999), a negative
redictive value of 89.36% (95% CI: 0.768–0.964) and a kappa coef-
cient of 91.7% (95% CI: 0.851–0.982).The range of the colorimetric scale of the reagent samples was
imilar between the serum and oral ﬂuid (ChemBio®) samples,
able 3
arameters of performance evaluation of the ImmunoComb® II by using different oral co
Parameters Oral ﬂuid collec
ChemBio®
Sensitivity (95% CI)a 100.0 (0.9351–1
Speciﬁcity (95% CI)a 100.0 (0.9001–1
Positive predictive value (95% CI)a 100.0 (0.9351–1
Negative predictive value (95% CI)a 100.0 (0.9001–1
Spearman’s correlation coefﬁcient (p-value)† 0.987 (<0.000
Kappa statistic 100.0 
95% conﬁdence interval.
p < 0.05 (in bold) are statistically signiﬁcant.According to Ref. [17].
d Current study.
resulting in a median of 3.0 for both specimens. There was no
variation among the non-reactive samples.
3.4. Stability of anti-HAV antibodies in oral samples collected in
difﬁcult-to-access areas
The stability of the anti-HAV antibodies was determined by
monitoring the ﬁve serum and oral ﬂuid (ChemBio®) matched sam-
ples at different time exposures and temperatures.
When samples were collected and stored at unstable storage
conditions for 15 days (temperature variation, 2–25 ◦C), anti-HAV
antibodies could be detected from the oral samples. When samples
were stored at 2–8 ◦C, there was no change in the anti-HAV anti-
bodies within the 180 ﬁrst days after collection. However, on day
210 after collection, a one-level decrease in the colorimetric scale
was observed for the reactive samples. Antibodies against hepatitis
A remained detectable in the oral ﬂuid samples for more than 210
days. A comparison of Salivette®, OraSure® and ChemBio® sample
stability based on both the literature and the results obtained in this
study is summarized in Table 5. The ChemBio® device exhibited the
◦the Salivette® and OraSure® devices, as has been observed in other
studies [14,17].
llection devices.
tion device
OraSure® Salivette®
.000) 96.36 (0.8748–0.9956) 92.73 (0.8242–0.9798
.000) 100.0 (0.9001–1.000) 100.0 (0.9001–1.000
.000) 100.0 (0.9328–1.000) 100.0 (0.9302–1.000
.000) 94.5 (0.8179–0.9934) 89.74 (0.7577–0.9714
1) 0.969 (<0.0001) 0.948 (<0.0001)
95.4 90.8
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Table  6
Summary of reports on performance data of oral ﬂuid collection devices.
Author Year Studied population Objective Antibodies detected Collection device Sensitivity (%) Speciﬁcity (%)
Ochinio et al. 1997 [7] General population Standardization IgG Salivette® 98.70 99.60
Oba  et al. 2000  [8] General  population Diagnostics IgM, IgG and IgA Omni-SAL® 82.10 100
Amado  et al. 2006  [10] Outbreak Diagnostics IgM and IgG OraSure 86.67 100
IgG
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dQuolin  et al. 2007 [24] General population Prevalence 
Current  Study 2011 General population Prevalence 
. Discussion
To date, HAV vaccination strategies have been implemented on
he basis of cost-effectiveness and epidemiological studies. Rou-
ine large-scale infant vaccination programs are not recommended
or individuals living in areas of high endemicity [18]. In 2006, the
.S. Advisory Committee on Immunization Practices (ACIP) [18]
ecommended routine HAV vaccination of all children aged 12–23
onths, irrespective of risk category or location, resulting in a sig-
iﬁcant decrease in hepatitis A incidence in the next year. A more
ecent assessment of hepatitis A vaccine coverage among USA chil-
ren between the ages of 12 and 23 months from 2006 through
009 revealed improved coverage that had reached a plateau, lead-
ng to a push for hepatitis A vaccination of all children beginning at
ge 12 months by immunization programs and vaccine providers
19].
In developed countries, the implementation of a nationwide
outine vaccination program against hepatitis A is still an impor-
ant issue, mainly because of the changing HAV epidemiological
attern in some regions. Although a vaccine against hepatitis A
as been licensed since 1995, some countries do not recommend
outine hepatitis A vaccination due to the cost of the vaccine and
ifferences in HAV epidemiology across the nation (for example,
hether the vaccine is indicated for the groups known to be at high
isk for the infection). In the epidemiological context, the utilization
f oral ﬂuid to determine HAV protection has been demonstrated
o be appropriate because of its advantages and high accuracy for
urveillance studies in different rate groups [7,8,10,14,20–22]. The
dvantages of oral specimen collection and testing and the perfor-
ance of several oral ﬂuid collection devices and modiﬁed EIAs
ave led to increased interest in the utilization of oral ﬂuid as a
urrogate for serum samples.
To  be useful for HAV epidemiological studies and the screening
f groups with a high seroprevalence rate of anti-HAV antibodies,
he EIAs originally designed for use on serum samples were mod-
ﬁed to detect the antibodies in oral ﬂuid; the levels of anti-HAV
ntibodies are lower in oral ﬂuid than in serum. As a result, an
mprovement in the sensitivity and speciﬁcity of the assays using
atched oral ﬂuid and serum samples has been demonstrated
n several studies [7,8,10]. However, some studies have reported
esults of HAV testing in oral ﬂuid collected from patients during
epatitis A outbreaks, during which oral ﬂuid is known to have
igher titers of anti-HAV antibodies [6,10]. Thus, the optimization
f EIAs for detecting anti-HAV antibodies in oral ﬂuid collected dur-
ng outbreaks does not appear to be appropriate to validate these
ssays for use in evaluating oral ﬂuid anti-HAV levels associated
ith vaccine-induced immunity. Moreover, the optimal oral ﬂuid
ollection device for the determination of anti-HAV status must
e identiﬁed because the commercial product used for specimen
ollection can affect the recovery of antibodies and thus yield a
ower accuracy result [7,8,23,24]. In the present study and in accor-
ance with a previous study, the use of oral ﬂuid for anti-HAV
ntibody detection was  optimized; the use of an oral ﬂuid sample
ithout dilution is ideal for the detection of anti-HAV antibodies
y a modiﬁed EIA [10]. The three commercial oral ﬂuid collection
evices yielded different values of sensitivity and speciﬁcity for the Oracol® 84.70 100
 and IgG ChemBio® 100 100
detection of anti-HAV antibodies. The efﬁciency of oral ﬂuid col-
lection devices in extracting antibodies can be affected by the
commercially available product used for their collection [24].
The  levels of IgG anti-HAV-speciﬁc antibodies vary widely
according to how immunity is acquired and the biological ﬂuid
assayed. Higher levels are detected in serum samples from patients
recently infected with HAV than in oral ﬂuid from vaccinated indi-
viduals [11]. The differences in the sensitivity rates found here
could be partially explained by false-negative results from the
OraSure® (2/25) and Salivette® (4/25) devices in the group of vacci-
nated individuals. Nevertheless, the speciﬁcity rates did not appear
to be affected by the use of different oral ﬂuid devices. Among
the devices used for oral ﬂuid collection, Salivette® had the lowest
sensitivity rate (92.73%), with four oral ﬂuid samples from vacci-
nated individuals testing negative for anti-HAV antibodies. These
results are in line with previous studies reporting negative results
when using this oral ﬂuid device [14,21,25]. The damaging effect
of plain cotton on the analytical performance of this device is con-
ceivably attributed to substances derived from the cotton, which
affect the results by interfering with the detection of antibodies
[26].
The efﬁciency of antibody elution from the device’s sorbent
material may  vary among the oral ﬂuid collection devices and may
reﬂect different procedures of collection. The ChemBio® device is
designed to speciﬁcally target the gums, which is the region of the
oral cavity most likely to be rich in crevicular ﬂuid; additionally,
the ChemBio® device is used more vigorously inside the mouth
than the other two  devices. This characteristic of the product may
explain why  oral ﬂuid samples collected by devices that speciﬁcally
target crevicular ﬂuid may  contain anti-HAV antibodies in quanti-
ties that more reliably reﬂect the levels in serum samples [27]. The
other devices, OraSure® and Salivette®, are placed inside the oral
cavity adjacent to the gums and thus have a similar collection pro-
cedure, as reported by a study comparing three different oral-ﬂuid
collection devices including OraSure® [15]. Nevertheless, OraSure®
performed better than Salivette®, a ﬁnding that may  be related to
substances that are present in the OraSure® device that stimulate
the transudation of immunoglobulins from the vascular space to
the oral cavity [14].
A  comparative analysis of the median color scale values revealed
higher values in samples from individuals with a natural immu-
nity to HAV than in those from HAV-vaccinated individuals. Of
the three oral collection devices tested, the results provided by
the ChemBio® device were the most similar to the results from
the reference serum samples. Additionally, the ChemBio® device
exhibited the best combination of evaluation performance param-
eters, which were higher than those reported in previous studies
(Table 6).
To  determine the effectiveness of the ChemBio® device and its
applicability in a surveillance setting as a substitute for serum
samples, we  performed an investigation of HAV infection in
difﬁcult-to-access areas of South Pantanal. Using samples col-
lected from individuals belonging to different communities, we
observed similar values of prevalence of anti-HAV antibodies
(79.01%) and anti-HAV seroprevalence (80.8%) in oral ﬂuid collected
with ChemBio®.
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The suitability of oral ﬂuid in an epidemiological scenario is
losely related to the stability of the sample. Because the stability
f the OraSure® and Salivette® collection devices has been pre-
iously reported in the literature, this study evaluated the effect
f these parameters only in oral ﬂuid samples collected with the
hemBio® device. The temperature variation during in-ﬁeld sam-
le storage and delayed processing did not signiﬁcantly interfere
ith the detection of anti-HAV antibodies among oral samples
hen compared to the serum results. Sample storage at temper-
tures of 2–8 ◦C caused no signiﬁcant changes during the ﬁrst 180
ays after collection. However, at day 210, a decrease of one level
n the colorimetric scale for reactive samples was observed, but
he qualitative results remained the same. This stability should
e considered in an epidemiological scenario in which there is
o refrigeration, in developing countries that can have large and
ifﬁcult to accommodate variations in temperature [28], or when
amples are sent to the laboratory by mail service [23].
The  collection methodology and sample preservation by the use
f stabilizers in the ChemBio® device were considered an impor-
ant strategy to avoid the problems of rapid antibody degradation
uring storage as reported by Gröschl and colleagues [26] for other
ollection devices. In this study, we observed that this preservation
as sufﬁcient to increase the stability of the sample. Thus, these
esults showed that the ChemBio® device is suitable for vaccina-
ion and epidemiological surveillance in difﬁcult-to-access areas
ecause freezing is not required for sample storage.
. Conclusion
Oral ﬂuid samples collected with the ChemBio®, OraSure® and
alivette® devices provided qualitative results that were sufﬁ-
ient for detecting anti-HAV antibodies under optimal conditions.
owever, the ChemBio® device had the best performance in the
ptimization panel, and the stability of samples collected with this
evice demonstrated that this device was most appropriate for a
urveillance scenario.
Moreover,  oral ﬂuid can be used to detect low-level, speciﬁc
ntibody levels in vaccinated individuals, although the choice of the
ppropriate collection device is essential to evaluate HAV antibod-
es in difﬁcult-to-access areas. Oral ﬂuid was used to demonstrate
hat it is possible to collect this clinical specimen when ideal storage
onditions are not available, which is indispensable to determining
he epidemiological proﬁle of the disease and selecting age groups
or vaccination.
inancial support
Fundac¸ ão de Amparo à Pesquisa do Estado do Rio de Janeiro
FAPERJ) and Conselho Nacional de Desenvolvimento Cientíﬁco e
ecnológico (CNPq).
eferences[1] Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine
2000;18:57–60.
[2]  Vitral CL, Gaspar AMC, Souto FJD. Epidemiological pattern and mortality rates
for hepatitis A in Brazil: 1980–2002 – a review. Mem  Inst Oswaldo Cruz
2006;101(2):119–27.
[ 30 (2012) 6421– 6426
[3] Arankalle VA, Chadha MS.  Who  should receive hepatitis A vaccine. J Viral Hepat
2003;10(May):157–8.
[4]  Vitral CL, Yoshida CFT, Lemos ER, Teixeira CS, Gaspar AMC. Age-speciﬁc preva-
lence of antibodies to hepatitis A in children and adolescents from Rio de
Janeiro, Brazil, 1978 and 1995. Relationship of prevalence to environmental
factors. Mem  Inst Oswaldo Cruz 1998;93:1–5.
[5]  De Cock L, Hutse V, Verhaegen E, Quoilin S, Vandenberghe H, Vranckx R. Detec-
tion of HCV antibodies in oral ﬂuid. J Virol Methods 2004;122:179–83.
[6] Parry JV. Detection of viral antibodies in saliva specimens as an alternative to
serum. J Clin Chem Clin Biochem 1989;27:245–6.
[7]  Ochnio JJ, Scheifele DH, Ho M,  Mitchell LA. New, ultrasensitive enzyme
immunoassay for detecting vaccine and disease-induced hepatitis A virus-
speciﬁc immunoglobulin G in saliva. J Clin Microbiol 1997;35(1):98–101.
[8] Oba IT, Spina AMM,  Saraceni CP, Lemos MF,  Senhoras RCFA, Moreira RC, et al.
Detection of hepatitis A antibodies by ELISA using saliva as clinical samples.
Rev Inst Med  Trop São Paulo 2000;42(4):197–200.
[9]  Morris-Cunnington MC,  Edmunds WJ,  Miller E, Brown DWG.  A population-
based seroprevalence study of hepatitis A virus using oral ﬂuid in England and
Wales. Am J Epidemiol 2004;159:786–94.
10] Amado LA, Villar LM,  De Paula VS, De Almeida AJ, Gaspar AMC. Detection of
hepatitis A, B and C virus-speciﬁc antibodies using oral ﬂuid for epidemiological
studies. Mem  Inst Oswaldo Cruz 2006;101:149–55.
11]  Zaaijer HL, Leentwaar-Kuijpers A, Rotman H, Lelie PN. Hepatitis A antibody
titers after infection and immunization: implication for passive and active
immunization. J Med  Virol 1993;40:22–7.
12] Challacombe SJ, Russell MW,  Hawkes J. Passage of intact IgG from plasma to
the oral cavity via crevicular ﬂuid. Clin Exp Immunol 1978;34(3):417–22.
13] Roitt I, Lehner T. Oral immunity of oral disease. 2nd ed. Blackwell: Oxford; 1983.
p. 279–304.
14]  Parry JV. Simple and reliable salivary test for HIV and hepatitis A and B virus
diagnosis and surveillance. Ann N Y Acad Sci 1993;694:216–33.
15] Nokes DJ, Enquselassie F, Vyse A, Nigatu W,  Cutts FT, Brown DW.  An
evaluation of oral-ﬂuid collection devices for the determination of rubella
antibody status in a rural Ethiopian community. Trans R Soc Trop Med Hyg
1998;92(November–December (6)):679–85.
16] Altman DG. Practical statistics for medical research. London: Chapman and
Hall/CRC; 1991. p. 611.
17] Stark K, Warnecke C, Brinkmann V, Gelderblom HR,  Bienzle U, Pauli G. Sen-
sitivity of HIV antibody detection in saliva. Med  Microbiol Immunol (Berl)
1993;182(3):147–51.
18]  Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A,
Bell BP. Prevention of hepatitis A through active or passive immunization: rec-
ommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR  Recomm Rep 2006;19(May (55) (RR-7)):1–23.
19] Centers for Disease Control Prevention (CDC). Hepatitis A vaccination coverage
among U.S. children aged 12–23 months – immunization information sys-
tem sentinel sites, 2006–2009. MMWR  Morb Mortal Wkly Rep 2010;59(July
(25)):776–9.
20] McIntyre PG, Laszlo J, Appleyard K, Ogden GR. Modiﬁed enzyme immunoassay
to detect hepatitis C virus antibodies in oral ﬂuid. Eur J Microbiol Infect Dis
1996;15:882–4.
21] Judd A, Parry J, Hickman M,  McDonald T, Jordan L, Lewis K, et al. Evaluation of
a modiﬁed commercial assay in detecting antibody to hepatitis C virus in oral
ﬂuids and dried blood spots. J Med  Virol 2003;71:49–55.
22]  Tourinho RS, Amado LA, Villar LM,  Sampaio DV, Moraes AC, Rodrigues do ÓKM,
et al. Importance of the cutoff ratio for detecting antibodies against hepatitis A
virus in oral ﬂuids by enzyme immunoassay. J Virol Methods 2011;173:169–74.
23] Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, et al. A
population-based prevalence study of hepatitis A, B and C virus using oral ﬂuid
in Flanders, Belgium. Eur J Epidemiol 2007;22(3):195–202.
24]  Chang CK, Cohen ME,  Bienek DR. Efﬁciency of oral ﬂuid collection devices in
extracting antibodies. Oral Microbiol Immunol 2009;24(3):231–5.
25] van den Akker R, van den Hoek JA, van den Akker WM,  Kooy H, Vijge E,
Roosendaal G, et al. Detection of HIV antibodies in saliva as a tool for epidemi-
ological studies. AIDS 1992;6(September (9)):953–7.
26]  Gröschl M,  Köhler H, Topf HG, Rupprecht T, Rauh M.  Evaluation of saliva col-
lection devices for the analysis of steroids, peptides and therapeutic drugs. J
Pharm Biomed Anal 2008;47(July (3)):478–86.
27]  Vyse AJ, Chen BJ, Ramsay ME.  A comparison of oral ﬂuid collection devices
for use in the surveillance of virus diseases in children. Public Health
2001;115:201–7.
28] Nokes DJ, Enquselassie F, Nigatu W,  Vyse AJ, Cohen BJ, Brown DW,  et al. Has oral
ﬂuid the potential to replace serum for the evaluation of population immunity
levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull World
Health Organ 2001;79(7):588.
